ILMN vs IQV
Illumina, Inc. and IQVIA, both Healthcare
IQVIA is the larger company at $43B against $42B. On trailing earnings IQV is the cheaper of the two at a P/E of 32.5 against 51.6, a gap that is only a bargain if the two are growing at similar rates. Over the past year ILMN returned +172% against +40% for IQV. The RyuScore puts IQV ahead, 66 against 28 out of 100.
| Figure | ILMN | IQV |
|---|---|---|
| Last close | $277 | $262 |
| Market cap | $42B | $43B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 51.6 | 32.5 |
| 1-year return | +172% | +40% |
| 5-year return | -37% | +1.8% |
| RyuScoresector-relative, 1–10 | 28/100 | 66/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Illumina, Inc.
Revenue of $1.2B in Q2 2026, net income $207M. Its largest reported line is United States And Canada, 56% of the disclosed total.
IQVIA
Revenue of $4.2B in Q1 2026, net income $274M. Its largest reported line is Research And Development Solutions, 56% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.